

...continued from previous page.

BASIS FOR OFFER PRICE

Date of Transfer	Name of Transferor	Name of Transferee	No. of Securities	% of pre Offer paid up share capital on fully diluted fully diluted Basis	Equity / Convertible Security	Face value (₹)	Price per Security (₹)	Nature of Consideration	Total Consideration (₹ in million)
March 27, 2025	Malani Ventures Private Limited	Bombay Mercantile & Leasing Co. Limited	111,111	0.09%	CCPS	10	45	Cash	5.00
March 27, 2025	Malani Ventures Private Limited	Mukesh Saraswat	111,111	0.09%	CCPS	10	45	Cash	5.00
March 26, 2025	Malani Ventures Private Limited	Pavan Kumar. A.	111,111	0.09%	CCPS	10	45	Cash	5.00
March 26, 2025	Malani Ventures Private Limited	Sripal H Chajer Huf	111,111	0.09%	CCPS	10	45	Cash	5.00
March 26, 2025	Malani Ventures Private Limited	Saurabh Agarwal	111,111	0.09%	CCPS	10	45	Cash	5.00
March 26, 2025	Malani Ventures Private Limited	Ashish Poddar Huf	111,111	0.09%	CCPS	10	45	Cash	5.00
March 27, 2025	Malani Ventures Private Limited	Gunjan Amit Agarwal	100,000	0.08%	CCPS	10	45	Cash	4.50
March 27, 2025	Malani Ventures Private Limited	Vinodray Vithaldas Donga	100,000	0.08%	CCPS	10	45	Cash	4.50
March 27, 2025	Malani Ventures Private Limited	Khushal Nilesh Sangani	100,000	0.08%	CCPS	10	45	Cash	4.50
March 28, 2025	Malani Ventures Private Limited	Ramchandra Ramanlal Patel (Huf)	91,667	0.07%	CCPS	10	45	Cash	4.13
March 28, 2025	Malani Ventures Private Limited	Bhavin Chandulal Patel	75,000	0.06%	CCPS	10	45	Cash	3.38
March 27, 2025	Malani Ventures Private Limited	Rachana Sanjay Agarwal	55,556	0.05%	CCPS	10	45	Cash	2.50
March 28, 2025	Malani Ventures Private Limited	Kamleshbhai Bhailalbhai Patel	55,556	0.05%	CCPS	10	45	Cash	2.50
March 28, 2025	Malani Ventures Private Limited	Fierce Realty Lip	55,556	0.05%	CCPS	10	45	Cash	2.50
March 28, 2025	Malani Ventures Private Limited	V Core Brains Lip	55,556	0.05%	CCPS	10	45	Cash	2.50
March 28, 2025	Malani Ventures Private Limited	Vraj Mahesh Patel	55,556	0.05%	CCPS	10	45	Cash	2.50
March 27, 2025	Malani Ventures Private Limited	Sachin Tapania (Huf)	55,556	0.05%	CCPS	10	45	Cash	2.50
March 28, 2025	Malani Ventures Private Limited	Gaurang Kantilal Sherawala	55,556	0.05%	CCPS	10	45	Cash	2.50
March 28, 2025	Malani Ventures Private Limited	Manav Vijaykumar Kothari	55,556	0.05%	CCPS	10	45	Cash	2.50
March 28, 2025	Malani Ventures Private Limited	Hemang Jayant Shah	55,556	0.05%	CCPS	10	45	Cash	2.50
March 28, 2025	Malani Ventures Private Limited	Real Value Finloan Services Private Limited	55,556	0.05%	CCPS	10	45	Cash	2.50
March 28, 2025	Malani Ventures Private Limited	Shipa Poly Pack Private Limited	55,556	0.05%	CCPS	10	45	Cash	2.50
March 28, 2025	Malani Ventures Private Limited	Mrugesh Deepakbhai Kothari	55,556	0.05%	CCPS	10	45	Cash	2.50
March 28, 2025	Malani Ventures Private Limited	Savo Joseph Fernandez	55,556	0.05%	CCPS	10	45	Cash	2.50
March 28, 2025	Malani Ventures Private Limited	Jugal Mangilal Kanugoo Huf	55,556	0.05%	CCPS	10	45	Cash	2.50
March 28, 2025	Malani Ventures Private Limited	Kantilal Kacharalal Patel	55,555	0.05%	CCPS	10	45	Cash	2.50
March 28, 2025	Malani Ventures Private Limited	Yastika Bhatia	55,555	0.05%	CCPS	10	45	Cash	2.50
March 28, 2025	Malani Ventures Private Limited	Vijay Vinod Patel	55,555	0.05%	CCPS	10	45	Cash	2.50
March 28, 2025	Malani Ventures Private Limited	Kalpana Umeshbhai Shah	55,555	0.05%	CCPS	10	45	Cash	2.50
March 28, 2025	Malani Ventures Private Limited	Gandhi Dipsha Forum	55,555	0.05%	CCPS	10	45	Cash	2.50
March 28, 2025	Malani Ventures Private Limited	Hitesh Harishkumar Agrawal	55,555	0.05%	CCPS	10	45	Cash	2.50
March 28, 2025	Malani Ventures Private Limited	Bhavin Becharbhai Mangrolia	55,555	0.05%	CCPS	10	45	Cash	2.50
March 28, 2025	Malani Ventures Private Limited	Patel Kantibhai C.	55,555	0.05%	CCPS	10	45	Cash	2.50
March 28, 2025	Malani Ventures Private Limited	Yayalokumar Rajendrakumar Bhatt	55,555	0.05%	CCPS	10	45	Cash	2.50
March 28, 2025	Malani Ventures Private Limited	Vaishaliben Jayeshbhai Patel	55,555	0.05%	CCPS	10	45	Cash	2.50
March 28, 2025	Malani Ventures Private Limited	Bhupendra Shantilal Mehta	55,555	0.05%	CCPS	10	45	Cash	2.50
March 27, 2025	Malani Ventures Private Limited	Hiten Chaturbhai Babariya	52,657	0.04%	CCPS	10	45	Cash	2.37
March 27, 2025	Malani Ventures Private Limited	Tapas Jain	50,000	0.04%	CCPS	10	45	Cash	2.25
March 27, 2025	Malani Ventures Private Limited	Vinod Kumar Bansal	50,000	0.04%	CCPS	10	45	Cash	2.25
Total			2,44,16,424.00						1,049.30
Weighted average cost of Acquisition (WACA) per share is									₹42.98

Note:- The Company has converted 12,208,212 Compulsorily Convertible Preference Shares (CCPS) of face value ₹10 each, into 12,290,705 equity shares of face value ₹1 each, at a conversion ratio of 1.006757138 on April 20, 2026.

c) Weighted average cost of acquisition, Floor Price and Cap Price

Based on the disclosures in (a), (b), and (c) above, the weighted average cost of acquisition of Specified Securities where such issuance or transfer is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-Offer capital before such transaction(s)) as compared with the Floor Price and Cap Price is set forth below:

Past Transactions	Weighted average cost of acquisition (₹)	Floor Price ₹ 42	Cap Price ₹ 45
Weighted average cost of acquisition (WACA) of Primary issuances	44.70	0.94	1.01
Weighted average cost of acquisition (WACA) of secondary transactions	42.98	0.98	1.05

7. Justification for Basis of Offer Price**(a) Explanation for Cap Price being 1.01 times of WACA of primary issuances and 1.05 times of secondary transactions of Equity Shares of face value of ₹1 each (as disclosed above) along with our Company's KPIs and financial ratios for the Fiscals 2025, 2024 and 2023:**

- The majority of our revenue from operations is attributed to products across an integrated nutrition value chain, spanning micronutrient premixes, B2B2C fortification solutions, branded clinical nutrition products and therapeutic Ready-to-Use Foods, making us one of the few players in India with end-to-end capabilities across the full nutrition spectrum. As per the CARE Report, we are one of the largest premix players in India, offering customised vitamin and mineral premixes to leading Indian and multinational FMCG companies, and one of the largest licensed suppliers of Micronutrient Powders (MNP) under UN programmes.
- We market an established portfolio of wellness and clinical nutrition brands such as PENTASURE, OBESIGO, PEDIAGOLD and NUTRONE, catering to diverse therapy areas including diabetes, renal, bariatric, hepatic, paediatric and general wellness nutrition, with regulatory approvals obtained in over 14 countries.
- We serve a diversified customer base across B2C, B2B2C and ESG segments. During the nine-month period ended December 31, 2025, and in Fiscals 2025, 2024 and 2023, we served 423, 456, 491 and 462 customers respectively, of which 286, 294, 284 and 246 were repeat customers, evidencing strong client retention and revenue predictability.
- Our branded nutrition business is supported by a distribution network and doctor outreach across key therapy segments. We have relationships with distributors, healthcare institutions and medical practitioners, enabling market reach, product availability and prescription-led demand for our clinical nutrition brands. This network supports business expansion across geographies and growth in the branded segment.
- Revenue from Operations grew from ₹2,785.01 million in Fiscal 2023 to ₹3,249.29 million in Fiscal 2025 and reached ₹2,675.87 million for the nine months ended December 31, 2025. EBITDA improved from ₹171.74 million (EBITDA Margin: 6.17%) in Fiscal 2023 to ₹400.72 million (EBITDA Margin: 12.33%) in Fiscal 2025, and further to ₹375.54 million (EBITDA Margin: 14.03%) for the nine months ended December 31, 2025.
- PAT grew from ₹58.24 million (PAT Margin: 2.07%) in Fiscal 2023 to ₹243.77 million (PAT Margin: 7.36%) in Fiscal 2025, and reached ₹270.33 million (PAT Margin: 9.81%) for the nine months ended December 31, 2025, reflecting a strong structural improvement in profitability.
- As at and for the nine months ended December 31, 2025, our RoCE was 14.82%, RoE was 13.02%, Interest Coverage Ratio was 13.36, Debt-to-Equity Ratio was 0.18 and Current Ratio was 2.71, reflecting financial soundness, low leverage and healthy debt-servicing capability.

(b) Explanation for the Cap Price, being 1.01 times of WACA of primary issuances and 1.05 times of secondary transactions of Equity Shares (as disclosed above) in view of the external factors which may have influenced the pricing of the Offer:

- The India clinical nutrition market has demonstrated strong and sustained growth, increasing from ₹32,296 million in CY20 to ₹55,724 million in CY24, and is projected to reach ₹112,058 million by CY30, reflecting a CAGR of 14.4% during CY20–CY24 and 12.1% during CY25–CY30. The growth is driven by increasing prevalence of lifestyle diseases, rising awareness towards preventive healthcare, higher demand for therapeutic and disease-specific nutrition products, and institutionalisation of nutrition delivery across hospitals and healthcare channels. These industry trends are expected to create long-term growth opportunities for companies operating in the clinical and fortified nutrition segment, including our Company. (Source: CARE Report)
- Food fortification has been institutionalised through FSSAI regulations covering rice, wheat flour, milk, oil and salt. Government programmes, PM POSHAN (covering 120 million schoolchildren), ICDS (serving 82 million women and children) and PDS (targeting 300 million beneficiaries under fortified rice), create large, recurring institutional demand. As one of India's largest licensed MNP suppliers under UN programmes, we are structurally positioned to benefit from this policy-driven demand. (Source: CARE Report)
- India's clinical nutrition market is expanding on account of rising non-communicable diseases. Stunting affects 35.5% and wasting affects 19.3% of children under five (NFHS-5). Chronic Kidney Disease affects approximately 17% of Indian adults; and India's elderly population is projected to reach 194 million by 2031, materially expanding demand for therapeutic and geriatric nutrition, the core of our branded B2C segment.

8. The Offer Price is [a] times of the Face Value of the Equity Shares.

The Offer Price of ₹[a] has been determined by our Company in consultation with the BRLMs, on the basis of market demand from investors for Equity Shares, as determined through the Book Building Process, and is justified in view of the above qualitative and quantitative parameters. Investors should read the above-mentioned information along with "Risk Factors", "Our Business", "Management Discussion and Analysis of Financial Position and Results of Operations" and "Financial Information" on pages 30, 270, 488 and 407, of the RHP, respectively, to have a more informed view. The trading price of the Equity Shares could decline due to the factors mentioned in the "Risk Factors" on page 30 of the RHP and you may lose all or part of your investments.

ASBA # Simple, Safe, Smart way of Application!!!

Applications supported by blocked amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account. For further details, check section on ASBA.

**Mandatory in public issues.
No cheque will be accepted.**



UPI Now available in ASBA for Retail Individual Investors and Non - Institutional Investor applying in public issues where the application amounts is upto ₹ 5,00,000/-, applying through Registered Brokers, Syndicate, DPs and RTAs. UPI Bidder also have the option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account. Investors are required to ensure that the bank account used for their PAN. Bidders must ensure that their PAN is linked with Aadhaar and are in compliance with CBDT notification dated February 13, 2020, issued by the Central Board of Direct Taxes and the subsequent press releases, including press releases dated June 25, 2021 and September 17, 2021 and CBDT circular no. 7 of 2022, dated March 30, 2022 read with press release dated March 28, 2023 and any subsequent press releases in this regard.

ASBA has to be availed by all the investors except anchor investors. UPI may be availed by (i) Retail Individual Investors in the Retail Portion; (ii) Non-Institutional Investors with an application size of up to ₹ 500,000 in the Non-Institutional Portion. For details on the ASBA and UPI process, please refer to the details given in ASBA form and abridged prospectus and also please refer to the section "Offer Procedure" on page 577 of the RHP. The process is also available on the website of Association of Investment Bankers of India ("AIBI") and Stock Exchanges and in the General Information Document. ASBA bid-cum-application forms can be downloaded from the websites of the Stock Exchanges and can be obtained from the list of banks that is displayed on the website of SEBI at www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFirm=yes&intmid=43, respectively as updated from time to time. For the list of UPI apps and banks live on IPO, please refer to the link www.sebi.gov.in. UPI Bidders Bidding using the UPI mechanism may apply through the SCSBs and mobile applications whose names appear on the website of SEBI, as updated from time to time. ICICI Bank Limited and HDFC Bank Limited have been appointed as Sponsor Banks for the Offer, in accordance with the requirements of the SEBI Circular dated November 1, 2018 as amended. For Offer related queries, please contact the BRLM on their respective email IDs as mentioned below. For UPI related queries, investors can contact NPCI at the toll free number: 18001201740 and mail ID: ipo.upi@npci.org.in.

An indicative timetable in respect of the Offer is set out below:**Submission of Bids (other than Bids from Anchor Investors):**

Bid/Offer Period (except the Bid/Offer Closing Date)	
Submission and Revision in Bids	Only between 10.00 a.m. and 5.00 p.m. (Indian Standard Time ("IST"))
Bid/Offer Closing Date*	
Submission of electronic applications (online ASBA through 3-in-1 accounts) – For Retail Individual Bidders	Only between 10.00 a.m. and up to 5.00 p.m. IST
Submission of electronic application (bank ASBA through online channels like internet banking, mobile banking and syndicate ASBA applications through UPI as a payment mechanism where Bid Amount is up to ₹500,000)	Only between 10.00 a.m. and up to 4.00 p.m. IST
Submission of electronic applications (syndicate non-retail, non- individual applications of QIBs and NIIIs)	Only between 10.00 a.m. and up to 3.00 p.m. IST
Submission of physical applications (direct bank ASBA)	Only between 10.00 a.m. and up to 1.00 p.m. IST
Submission of physical applications (syndicate non-retail, non- individual applications where Bid Amount is more than ₹500,000)	Only between 10.00 a.m. and up to 12.00 p.m. IST
Modification/ Revision/cancellation of Bids	
Upward Revision of Bids by QIBs and Non-Institutional Bidders categories*	Only between 10.00 a.m. and up to 4.00 p.m. IST on Bid/ Offer Closing Date
Upward or downward Revision of Bids or cancellation of Bids by RIBs	Only between 10.00 a.m. and up to 5.00 p.m. IST

* UPI mandate end time and date shall be at 5 p.m. on the Bid/Offer Closing Date.

* QIBs and Non-Institutional Bidders can neither revise their bids downwards nor cancel / withdraw their Bids.

THE EQUITY SHARES OF OUR COMPANY WILL GET LISTED ON MAIN BOARD PLATFORMS OF BSE AND NSE

In case of any revision in the Price Band, the Bid/Offer Period will be extended by at least 3 (three) additional Working Days after such revision in the Price Band, subject to the Bid/Offer Period not exceeding 10 (ten) Working Days. In cases of force majeure, banking strike or similar circumstances, our Company may, for reasons to be recorded in writing, extend the Bid/Offer Period for a minimum of 1 (one) Working Day, subject to the Bid/Offer Period not exceeding 10 (ten) Working Days. Any revision in the Price Band and the revised Bid/Offer Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the website of the BRLMs and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and the Sponsor Bank, as applicable.

This Offer is being made in terms of Rule 19(2)(b) of the SCRR read with Regulation 31 of the SEBI ICDR Regulations. This Offer is being made for at least 25% of the post-Offer paid-up Equity Share capital of our Company. This Offer is being made through the Book Building Process in accordance with Regulation 6(1) of the SEBI ICDR Regulations wherein in terms of Regulation 32(1) of the SEBI ICDR Regulations, not more than 50% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") and such portion of the "QIB Portion", provided that our Company may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis, in accordance with the SEBI ICDR Regulations (the "Anchor Investor Portion"), of which 40% shall be reserved as follows: (i) 33.33% for domestic Mutual Funds; and (ii) 6.67% for Life Insurance Companies and Pension Funds, subject to valid Bids being received from domestic Mutual Funds, Life Insurance Companies and Pension Funds at or above the Anchor Investor Offer Price. In case the aggregate demand from Life Insurance Companies and Pension Funds is less than 6.67%, the remaining Equity Shares will be added to the portion allocated to domestic Mutual Funds, in accordance with the SEBI ICDR Regulations. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the remaining QIB Portion ("Net QIB Portion"). Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from the Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Offer shall be available for allocation on a proportionate basis to Non-Institutional Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price, out of which (a) one-third of such portion shall be reserved for Bidders with application size of more than ₹ 0.20 million and up to ₹1.00 million; and (b) two-thirds of such portion shall be reserved for Bidders with application size of more than ₹1.00 million provided that the unsubscribed portion in either of such sub-categories may be allocated to Bidders in the other sub-category of Non-Institutional Bidders; and not less than 35% of the Offer shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. All Bidders (except Anchor Investors) are mandatorily required to utilize the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA accounts and UPI ID in case of UPI Bidders using the UPI Mechanism, as applicable, pursuant to which their corresponding Bid Amount will be blocked by the Self Certified Syndicate Banks ("SCSBs") or by the Sponsor Banks under the UPI Mechanism, as the case may be, to the extent of the respective Bid Amounts. Anchor Investors are not permitted to participate in the Offer through the ASBA process. For details, see "Offer Procedure" on page 577 of the RHP.

Bidders/Applicants should note that DP ID, PAN, Client ID and UPI ID (for UPI Bidders bidding through the UPI Mechanism) are correctly filled in the Bid cum Application Form. The DP ID, PAN and Client ID provided in the Bid cum Application Form should match with the DP ID, PAN, Client ID available in the Depository database, otherwise, the Bid cum Application Form is liable to be rejected. Bidders/Applicants should ensure that the beneficiary account provided in the Bid cum Application Form is active. Bidders/Applicants should note that on the basis of the PAN, DP ID, Client ID and UPI ID (for UPI Bidders bidding through the UPI Mechanism) as provided in the Bid cum Application Form, the Bidder/Applicant may be deemed to have authorised the Depositories to provide to the Registrar to the Offer, any requested Demographic Details of the Bidder/Applicant as available on the records of the depositories. These Demographic Details may be used, among other things, for giving Allotment Advice or unblocking of ASBA Account or for other correspondence(s) related to the Offer. Bidders/Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay resulting from failure to update the Demographic Details would be at the Bidders/Applicants' sole risk. Investors must ensure that their PAN is linked with Aadhaar and are in compliance with CBDT notification dated February 13, 2020 and press release dated June 25, 2021, read with press

release dated September 17, 2021 and CBDT circular no. 7 of 2022, dated March 30, 2022 read with press release dated March 28, 2023 and any subsequent press releases in this regard.

Contents of the Memorandum of Association of our Company as regards its objects: For information on the main objects of our Company, please see the section "History and Certain Corporate Matters" on page 347 of the RHP. The Memorandum of Association of our Company is a material document for inspection in relation to the Offer. For further details, please see the section titled "Material Contracts and Documents for Inspection" on page 670 of the RHP.

Liability of the members of our Company: Limited by shares

Amount of share capital of our Company and Capital structure: As on the date of the RHP, the authorised share capital of the Company is ₹ 225,100,000 divided into 225,100,000 Equity Shares bearing face value of ₹ 1 each and ₹ 125,000,000 divided into 12,500,000 CCPS on face value of ₹10 each. The issued, subscribed and paid-up share capital of the Company is ₹ 122,918,109 divided into 122,918,109 Equity Shares bearing face value of ₹1 each. For details, please see the section titled "Capital Structure" on page 138 of the RHP.

Names of signatories to the Memorandum of Association of our Company and the number of Equity Shares subscribed by them: The names of the initial signatories of the Memorandum of Association of our Company along with their allotment are: Arun Purushottam Kelkar and Subhash Purushottam Kelkar: 100 equity shares each having face value of ₹10 each. For details of the share capital history of our Company, please see the section titled "Capital Structure" on page 138 of the RHP.

Listing: The Equity Shares to be offered through the Red Herring Prospectus are proposed to be listed on the Stock Exchanges. Our Company has received 'in-principle' approvals from the BSE and the NSE for the listing of the Equity Shares pursuant to letters each dated December 12, 2025. For the purposes of the Offer, the Designated Stock Exchange shall be NSE. A signed copy of the Red Herring Prospectus and the Prospectus shall be filed with the RoC in accordance with Section 26(4), 28 and 32 of the Companies Act, 2013. For details of the material contracts and documents available for inspection from the date of the Red Herring Prospectus until the Bid/Offer Closing Date, see "Material Contracts and Documents for Inspection" on page 670 of the RHP.

Disclaimer Clause of the Securities and Exchange Board of India ("SEBI"): SEBI only gives its observations on the Offer documents and this does not constitute approval of either the Offer or the specified securities or the RHP. The investors are advised to refer to page 554 of the RHP for the full text of the disclaimer clause of SEBI.

Disclaimer Clause of NSE (Designated Stock Exchange): It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Offer Document has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the RHP. The investors are advised to refer to page 558 of the RHP for the full text of the disclaimer clause of NSE.

Disclaimer Clause of BSE: It is to be distinctly understood that the permission given by BSE should not in any way be deemed or construed that the RHP has been cleared or approved by BSE nor does it certify the correctness or completeness of any of the contents of the RHP. The investors are advised to refer to page 557 of the RHP for the full text of the disclaimer clause of BSE.

Information for Bidders: It is to be distinctly understood that the permission given by Stock Exchanges to use their network and software of the Online IPO system should not in any way be deemed or construed that the compliance with various statutory and other requirements by the Company, BRLMs, etc. are cleared or approved by Stock Exchanges; nor does it in any manner warrant, certify or endorse the correctness or completeness of any of the compliance with the statutory and other requirements nor does it take any responsibility for the financial or other soundness of this issuer, its promoters, its management or any scheme or project of this issuer.

General Risk: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Company have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of the Red Herring Prospectus. Specific attention of the investors is invited to "Risk Factors" on page 30 of the RHP.

BOOK RUNNING LEAD MANAGERS		REGISTRAR TO THE OFFER	COMPANY SECRETARY AND COMPLIANCE OFFICER
Cumulative Capital Private Limited B 309-311, 215 Atrium, Nr. Courtyard Marriott Hotel, Andheri Kurla Road, Andheri East, Chakala MIDC, Mumbai, Maharashtra, India, 400093 Tel: +91 98196 62664/ 82000 52280 E-mail: hnl.ip@cumulativecapital.group Investor grievance e-mail: investor@cumulativecapital.group Website: www.cumulativecapital.group Contact person: Swapnilsagar Vithalrao/Jigar Bhanushali SEBI registration no.: INM000013129	Catalyst Capital Partners Private Limited 103A Shantilal Apts, S V Road, Near State Bank of India Borivali West, Mumbai – 400 092, Maharashtra, India Tel: +91 98190 45092 E-mail: mb@catalystcapital.in Investor grievance e-mail: compliance@catalystcapital.in Website: https://catalystcapital.in/ Contact person: Kaushik Gandhi SEBI registration number: INM000013068	KFin Technologies Limited 301, The Centrium, 3rd Floor, 57, Lal Bahadur Shastri Road, Nav Pada Kurla (West), Mumbai – 400 070, Maharashtra, India Tel: +91 40 6716 2222 E-mail: hexagon.ip@kfin.tech.com Investor grievance e-mail: einward.ris@kfin.tech.com Website: www.kfin.tech.com Contact Person: M. Murali Krishna SEBI Registration No.: INR000000221	Vedanti Swapnil Vartak 404, Global Chamber, Adarsh Nagar, Link Road, Andheri (West), Mumbai - 400 053, Maharashtra, India Tel: +91 22 62136710/711 E-Mail: cs.hnl@hexagonnutrition.com Website: www.hexagonnutrition.com Investors may contact our Company Secretary and Compliance Officer, the BRLMs or the Registrar to the Offer in case of any pre-Offer or post-Offer related grievances including non-receipt of letters of Allotment, non-credit of Allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders or non-receipt of funds by electronic mode, etc. For all Offer related queries and for redressal of complaints, Investors may also write to the BRLMs.

AVAILABILITY OF THE RHP: Investors are advised to refer to the RHP and the section titled "Risk Factors" on page 30 of the RHP, before applying in the Offer. A copy of the RHP shall be available on website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com, respectively, the website of the Company at www.hexagonnutrition.com, and on the websites of the Book Running Lead Managers ("BRLMs"), i.e. Cumulative Capital Private Limited and Catalyst Capital Partners Private Limited at www.cumulativecapital.group and <https://catalystcapital.in/>, respectively.